Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZL0104
- Development stage
- Preclinical
- Lead developer
- ShanghaiTech University
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cyclic Peptides → Modified Peptides → Peptides
- Administration
- Intravenous
01
Overview
ZL0104 (also known as HT448) is a DOTA-conjugated bicyclic peptide precursor designed to target the urokinase-type plasminogen activator receptor (uPAR). When radiolabeled with gallium-68 to form [68Ga]Ga-ZL0104, it serves as a positron emission tomography (PET) imaging tracer. Developed by researchers at ShanghaiTech University, this radiotracer is designed for the early detection and monitoring of pulmonary fibrosis, such as bleomycin-induced and radiation-induced pulmonary fibrosis. uPAR is highly upregulated during tissue remodeling and inflammatory responses associated with fibrosis, making it a sensitive biomarker. Preclinical studies demonstrate that [68Ga]Ga-ZL0104 can detect early molecular changes in pulmonary fibrosis before morphological alterations become visible on high-resolution computed tomography (HRCT).
- Other names
- 68Ga-HT44868Ga-ZL0104[68Ga]Ga-HT448[68Ga]Ga-ZL0104
02
Targets
PLAUR (Urokinase plasminogen activator receptor)
Beyond the preview
Go deeper on ZL0104.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZL0104.